Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small ...

The answer really is just diet and exercise − there are no therapies yet,” said Kristen Fortney, CEO of BioAge, a biotech company developing drugs to treat diseases related to aging.

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies ...

As a postdoctoral researcher at Stanford University, Kristen Fortney used bioinformatics to study the genetics of supercentenarians — people who live to the age of 110 and beyond. Now she is at ...

The financing is enough to last almost three years, at least, CEO Kristen Fortney, Ph.D., said in an interview with Fierce Biotech ahead of Tuesday’s announcement. Atop the to-do list is a phase ...

BioAge was co-founded in 2015 by CEO Kristen Fortney, whose background is in aging science. The heart of the company is a technology platform that analyzes human datasets to reveal insights about ...

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

Kristen Fortney, chief executive of California-based BioAge, said administering azelaprag with Mounjaro “may help promote healthier weight loss.” The trial is expected to begin in mid-2024 ...

One concern about the GLP-1 class of metabolic disorder drugs is that the weight patients lose includes muscle as well as fat. BioAge Labs wants to test whether its experimental medication, dosed ...

CEO Kristen Fortney said, "We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested ...